Year: 2012
Type: review
Abstract: Common variable immunodeficiency (CVID) describes a heterogeneous subset of hypogammaglobulinemias of unknown etiology. Typically, patients present with recurrent bacterial infections of the respiratory and gastrointestinal tract. A significant proportion of CVID patients develops additional autoimmune, inflammatory or lymphoproliferative complications. CVID is the most frequent symptomatic primary immunodeficiency encountered in adults. Informative monogenetic defects have been found in single patients and families but in most cases the pathogenesis is still elusive. Numerous immunological studies have demonstrated phenotypic and functional abnormalities of T cells, B cells and antigen-presenting cells. A hallmark is the impaired memory B-cell formation that has been taken advantage of for classifying CVID patients. Clinical multi-center studies have demonstrated a correlation between immunological markers and clinical presentation. Long-term outcome is significantly influenced by delay of diagnosis and treatment and the presence of chronic inflammatory complications. While immunoglobulin replacement therapy plus antibiotics can control infections in most cases, patients with non-infectious inflammatory complications such as granulomatous inflammation, interstitial lung disease, inflammatory bowel disease, lymphoproliferation and developing malignancies still represent a therapeutic challenge. In this review we provide a systematic overview of the immunological, clinical, diagnostic and therapeutic aspects of CVID and highlight recent developments in these fields.
Source: Arthritis Research & Therapy
DOI: 10.1186/ar4032
Authors: Ulrich Salzer, Klaus Warnatz, Hans Peter
Institution: University Medical Center Freiburg
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: common variable immunodeficiency, hypogammaglobulinemia, primary immunodeficiency, recurrent bacterial infections, autoimmune complications, lymphoproliferative disorders, memory B cells, T cell abnormalities, B cell abnormalities, antigen-presenting cells, immunoglobulin replacement therapy, granulomatous inflammation, interstitial lung disease, inflammatory bowel disease, cancer risk, diagnosis, treatment
Open Access status: gold
Estimated APC paid: $3,690
OpenAlex ID: W2154926046
